keyword
https://read.qxmd.com/read/38652475/cdh1-genotype-exploration-in-women-with-hereditary-lobular-breast-cancer-phenotype
#1
JOURNAL ARTICLE
Giovanni Corso, Elena Marino, Cristina Zanzottera, Carla Oliveira, Loris Bernard, Debora Macis, Joana Figueiredo, Joana Pereira, Patrícia Carneiro, Giulia Massari, Massimo Barberis, Alessandra Margherita De Scalzi, Sergio Vincenzo Taormina, Elham Sajjadi, Claudia Sangalli, Sara Gandini, Oriana D'Ecclesiis, Cristina Maria Trovato, Anna Rotili, Filippo Pesapane, Luca Nicosia, Carlo La Vecchia, Viviana Galimberti, Elena Guerini-Rocco, Bernardo Bonanni, Paolo Veronesi
IMPORTANCE: Pathogenic or likely pathogenic (P/LP) germline CDH1 variants are associated with risk for diffuse gastric cancer and lobular breast cancer (LBC) in the so-called hereditary diffuse gastric cancer (HDGC) syndrome. However, in some circumstances, LBC can be the first manifestation of this syndrome in the absence of diffuse gastric cancer manifestation. OBJECTIVES: To evaluate the frequency of germline CDH1 variants in women with the hereditary LBC (HLBC) phenotype, somatic CDH1 gene inactivation in germline CDH1 variant carriers' tumor samples, and the association of genetic profiles with clinical-pathological data and survival...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38651796/persistent-cytopenia-after-cd19-car-t-therapy-in-relapsed-refractory-dlbcl-patients-could-be-a-predictor-of-efficacy-and-side-effects
#2
JOURNAL ARTICLE
Jingyi Li, Juan Mu, Jia Wang, Xin Li, Qing Li, Yili Jiang, Rui Cui, Qi Deng
Hematological toxicity is a severe adverse event (AE) in anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the pathophysiological mechanism underlying prolonged cytopenia and the relationship between persistent cytopenia, efficacy, and AEs after anti-CD19 CAR T cell therapy are unknown. Therefore, this study explored whether persistent cytopenia after anti-CD19 CAR T cell therapy in patients with R/R DLBCL can predict therapeutic efficacy and AEs...
2024: Cell Transplantation
https://read.qxmd.com/read/38651072/downregulation-of-nat1-expression-is-associated-with-poor-prognosis-and-immune-infiltration-in-coad
#3
JOURNAL ARTICLE
Houxi Xu, Hongqun Zhang, Songxian Sun, Jingyuan Zhang, Jiege Huo, Chunxiang Zhou
BACKGROUND: An increasing corpus of evidence has identified the involvement of N-acetyltransferase 1 (NAT1), a member of the NAT family, in the progression of various cancers. However, the specific function of NAT1 in colon cancer (COAD) remains elusive. This study aims to decip her the role of NAT1 in COAD and its associated mechanisms. METHODS: The Tumor Immunity Evaluation Resource (TIMER), The Cancer Genome Atlas (TCGA), and the Gene Expression Omnibus (GEO) databases were employed to assess the NAT1 expression level in COAD...
2024: Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/38649894/arginine-linked-hpv-associated-e7-displaying-bacteria-derived-outer-membrane-vesicles-as-a-potent-antigen-specific-cancer-vaccine
#4
JOURNAL ARTICLE
Suyang Wang, Chao-Cheng Chen, Ming-Hung Hu, Michelle Cheng, Hsin-Fang Tu, Ya-Chea Tsai, Jr-Ming Yang, T C Wu, Chuan-Hsiang Huang, Chien-Fu Hung
BACKGROUND: Bacteria-based cancer therapy have demonstrated innovative strategies to combat tumors. Recent studies have focused on gram-negative bacterial outer membrane vesicles (OMVs) as a novel cancer immunotherapy strategy due to its intrinsic properties as a versatile carrier. METHOD: Here, we developed an Human Papillomavirus (HPV)-associated E7 antigen displaying Salmonella-derived OMV vaccine, utilizing a Poly(L-arginine) cell penetrating peptide (CPP) to enhance HPV16 E7 (aa49-67) H-2 Db and OMV affinity, termed SOMV-9RE7...
April 22, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38648796/tight-junction-proteins-as-therapeutic-targets-to-treat-liver-fibrosis-and-hepatocellular-carcinoma
#5
JOURNAL ARTICLE
Antonio Saviano, Natascha Roehlen, Thomas F Baumert
In the last decade tight junction proteins exposed at the surface of liver or cancer cells have been uncovered as mediators of liver disease biology: Claudin-1 and Occludin are host factors for hepatitis C virus entry and Claudin-1 has been identified as a driver for liver fibrosis and hepatocellular carcinoma (HCC). Moreover, Claudins have emerged as therapeutic targets for liver disease and HCC. CLDN1 expression is upregulated in liver fibrosis and HCC. Monoclonal antibodies (mAbs) targeting Claudin-1 have completed preclinical proof-of-concept studies for treatment of liver fibrosis and HCC and are currently in clinical development for advanced liver fibrosis...
April 22, 2024: Seminars in Liver Disease
https://read.qxmd.com/read/38646863/living-beyond-restriction-lbr-promotes-cellular-immortalization-by-suppressing-genomic-instability-and-senescence
#6
JOURNAL ARTICLE
Haebeen Choi, Chanhee Kang
Cellular immortalization is a complex process that requires multiple genetic alterations to overcome restricting barriers, including senescence. Not surprisingly, many of these alterations are associated with cancer; two tumor suppressor pathways, the cellular tumor antigen p53 and p16-Retinoblastoma (RB) pathways, are the best-characterized examples, but their mutations alone are known to be insufficient to drive full immortalization. En et al. identified a role for the lamin B receptor (LBR) in promoting cellular proliferation and immortalization in p53- and RB-deficient cells by maintaining their genome integrity and suppressing senescence...
April 22, 2024: FEBS Journal
https://read.qxmd.com/read/38646638/hypofractionated-radiotherapy-combined-with-lenalidomide-improves-systemic-antitumor-activity-in-mouse-solid-tumor-models
#7
JOURNAL ARTICLE
Kateryna Onyshchenko, Ren Luo, Xi Rao, Xuanwei Zhang, Simone Gaedicke, Anca-Ligia Grosu, Elke Firat, Gabriele Niedermann
Background: Hypofractionated radiotherapy (hRT) can induce a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade (ICB). However, clinically, this effect is still rare, and ICB-mediated adverse events are common. Lenalidomide (lena) is an anti-angiogenic and immunomodulatory drug used in the treatment of hematologic malignancies. We here investigated in solid tumor models whether lena can enhance the abscopal effect in double combination with hRT...
2024: Theranostics
https://read.qxmd.com/read/38646539/pathways-and-molecules-for-overcoming-immunotolerance-in-metastatic-gastrointestinal-tumors
#8
REVIEW
Qixin Gan, Yue Li, Yuejun Li, Haifen Liu, Daochuan Chen, Lanxiang Liu, Churan Peng
Worldwide, gastrointestinal (GI) cancer is recognized as one of the leading malignancies diagnosed in both genders, with mortality largely attributed to metastatic dissemination. It has been identified that in GI cancer, a variety of signaling pathways and key molecules are modified, leading to the emergence of an immunotolerance phenotype. Such modifications are pivotal in the malignancy's evasion of immune detection. Thus, a thorough analysis of the pathways and molecules contributing to GI cancer's immunotolerance is vital for advancing our comprehension and propelling the creation of efficacious pharmacological treatments...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38646501/progress-in-cancer-research-on-the-regulator-of-phagocytosis-cd47-which-determines-the-fate-of-tumor-cells-review
#9
REVIEW
Fan Wu, Hongyuan Pang, Fan Li, Mengqing Hua, Chuanwang Song, Jie Tang
Cluster of differentiation 47 (CD47) is a transmembrane protein that is widely and moderately expressed on the surface of various cells and can have an essential role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis and other related responses by binding to its ligands, integrins, thrombospondin-1 and signal regulatory protein α. The poor prognosis of cancer patients is closely associated with high expression of CD47 in glioblastoma, ovarian cancer, breast cancer, bladder cancer, colon cancer and hepatocellular carcinoma...
June 2024: Oncology Letters
https://read.qxmd.com/read/38645737/periocular-sebaceous-carcinoma-a-case-audit-from-the-national-specialist-ophthalmic-pathology-service-in-liverpool-from-2009-to-2022-to-assess-the-diagnostic-utility-of-prame-expression
#10
JOURNAL ARTICLE
Amizatul Aini Salleh, Yamini Krishna, Sarah E Coupland
INTRODUCTION: Periocular sebaceous carcinoma (PSC) remains a common diagnostic pitfall both clinically and histomorphologically. PRAME (preferentially expressed antigen in melanoma) has been studied in the various neoplasms as proposed as diagnostic and therapeutic markers. PRAME is expressed in normal sebaceous units and in some sebaceous lesions; however, its utility in sebaceous carcinoma diagnosis has not yet been extensively investigated. We conducted a 13-year retrospective review of the patients diagnosed with PSC at the National Specialist Ophthalmic Pathology Service in Liverpool...
April 2024: Ocular Oncology and Pathology
https://read.qxmd.com/read/38645666/deleting-suv39h1-in-car-t-cells-epigenetically-enhances-the-antitumor-function
#11
JOURNAL ARTICLE
Yuning Wang, Guo Zhao, Shuhang Wang, Ning Li
SUV39H1 ablation in CAR-T cells epigenetically enhances the antitumor function (by Figdraw). (A) Schematic illustration of SUV39H1 ablation-mediated enhanced antitumor function of CAR-T cells. Functional CAR-T cells eventually transformed into dysfunctional exhausted CAR-T cells under the exposure of chronic tumor antigens, accompanied by reduced proliferation level, effector function, and stemness/memory characteristics, thereby limiting the antitumor activity so as to cause the recurrence of solid tumors...
May 2024: MedComm
https://read.qxmd.com/read/38645565/microenvironment-systemic-inflammatory-response-and-tumor-markers-considering-consensus-molecular-subtypes-of-colorectal-cancer
#12
JOURNAL ARTICLE
Anna Jakab, Árpád V Patai, Mónika Darvas, Karolina Tormássi-Bély, Tamás Micsik
Introduction: Colorectal carcinomas (CRC) are one of the most frequent malignancies worldwide. Based on gene expression profile analysis, CRCs can be classified into four distinct subtypes also known as the consensus molecular subtypes (CMS), which predict biological behaviour. Besides CMS, several other aspects of tumor microenvironment (TME) and systemic inflammatory response (SIR) influence the outcome of CRC patients. TME and inflammation have important role in the immune (CMS1) and mesenchymal (CMS4) subtypes, however, the relationship between these and systemic inflammation has not been assessed yet...
2024: Pathology Oncology Research: POR
https://read.qxmd.com/read/38643839/fusobacterium-nucleatum-carcinogenesis-and-drug-delivery-interventions
#13
REVIEW
Zhenzhen Chen, Leaf Huang
The microbiome has emerged as a significant biomarker and modulator in cancer development and treatment response. Recent research highlights the notable role of Fusobacterium nucleatum (F. nucleatum) in various tumor types, including breast, colorectal, esophageal, gastric, pancreatic, and lung cancers. Accumulating evidence suggests that the local microbial community forms an integral component of the tumor microenvironment, with bacterial communities within tumors displaying specificity to tumor types. Mechanistic investigations indicate that tumor-associated microbiota can directly influence tumor initiation, progression, and responses to chemotherapy or immunotherapy...
April 19, 2024: Advanced Drug Delivery Reviews
https://read.qxmd.com/read/38643541/tumor-associated-carbohydrate-antigens-of-muc1-implication-in-cancer-development
#14
REVIEW
Iwona Radziejewska
Glycosylation of cancerous epithelial MUC1 protein is specifically altered in comparison to that which is presented by healthy cells. One of such changes is appearing tumor-associated carbohydrate antigens (TACAs) which are rare in normal tissues and are highly correlated with poor clinical outcomes and cancer progression. This review summarizes and describes the role of Tn, T antigens, their sialylated forms as well as fucosylated Lewis epitopes in different aspects of tumor development, progression, and metastasis...
April 20, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38640255/co-targeting-ebv-lytic-as-well-as-latent-cycle-antigens-increases-t-cell-potency-against-lymphoma
#15
JOURNAL ARTICLE
Sandhya Sharma, Naren U Mehta, Tim Sauer, Dirk P Dittmer, Lisa A Rollins, Cliona M Rooney
The remarkable efficacy of Epstein-Barr virus (EBV) specific T-cells for the treatment of post-transplant lymphomas (PTLD) has not been reproduced for EBV+ malignancies outside the transplant setting. This is due in part to the heterogeneous expression and poor immunogenicity of the viral antigens expressed, namely LMPs 1 and 2, EBNA1, and BARF1 (type-2 (T2) latency). However, EBV lytic cycle proteins are also expressed in certain EBV+ malignancies, and since several EBV lytic cycle proteins are abundantly expressed, have oncogenic activity, and likely contribute to malignancy, we sought and identified viral lytic-cycle transcripts in EBV+ Hodgkin's lymphoma biopsies...
April 19, 2024: Blood Advances
https://read.qxmd.com/read/38639915/conditional-survival-analysis-and-real-time-prognosis-prediction-in-stage-iii-t3-t4-colon-cancer-patients-after-surgical-resection-a-seer-database-analysis
#16
JOURNAL ARTICLE
Hao Zeng, Xueyi Xue, Dongbo Chen, Biaohui Zheng, Baofeng Liang, Zhipeng Que, Dongbo Xu, Xiaojie Wang, Shuangming Lin
BACKGROUND: Conditional survival (CS) takes into consideration the duration of survival post-surgery and can provide valuable additional insights. The aim of this study was to investigate the risk factors associated with reduced one-year postoperative conditional survival in patients diagnosed with stage III T3-T4 colon cancer and real-time prognosis prediction. Furthermore, we aim to develop pertinent nomograms and predictive models. METHODS: Clinical data and survival outcomes of patients diagnosed with stage III T3-T4 colon cancer were obtained from the Surveillance, Epidemiology, and End Results (SEER) database, covering the period from 2010 to 2019...
April 19, 2024: International Journal of Colorectal Disease
https://read.qxmd.com/read/38639669/synthetic-biology-approaches-for-enhancing-safety-and-specificity-of-car-t-cell-therapies-for-solid-cancers
#17
JOURNAL ARTICLE
Grace C Russell, Yassin Hamzaoui, Daniel Rho, Gaurav Sutrave, Joseph S Choi, Dara S Missan, Gabrielle A Reckard, Michael P Gustafson, Gloria B Kim
CAR-T cell therapies have been successful in treating numerous hematologic malignancies as the T cell can be engineered to target a specific antigen associated with the disease. However, translating CAR-T cell therapies for solid cancers is proving more challenging due to the lack of truly tumor-associated antigens and the high risk of off-target toxicities. To combat this, numerous synthetic biology mechanisms are being incorporated to create safer and more specific CAR-T cells that can be spatiotemporally controlled with increased precision...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38638377/treatment-options-for-hepatocellular-carcinoma-using-immunotherapy-present-and-future
#18
REVIEW
Hongbin Wei, Chunlu Dong, Xun Li
Hepatocellular carcinoma (HCC) is a common cancer, and the body's immune responses greatly affect its progression and the prognosis of patients. Immunological suppression and the maintenance of self-tolerance in the tumor microenvironment are essential responses, and these form part of the theoretical foundations of immunotherapy. In this review, we first discuss the tumor microenvironment of HCC, describe immunosuppression in HCC, and review the major biomarkers used to track HCC progression and response to treatment...
April 28, 2024: Journal of Clinical and Translational Hepatology
https://read.qxmd.com/read/38638035/optimizing-the-design-and-geometry-of-t-cell-engaging-bispecific-antibodies-targeting-cea-in-colorectal-cancer
#19
JOURNAL ARTICLE
Abdullah Elsayed, Louis Plüss, Larissa Nideroest, Giulia Rotta, Marina Thoma, Nathan Zangger, Frederik Peissert, Stefanie K Pfister, Christian Pellegrino, Sheila Dakhel Plaza, Roberto De Luca, Markus G Manz, Annette Oxenius, Emanuele Puca, Cornelia Halin, Dario Neri
Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related deaths, with a 5-year survival rate of only 15%. T cell engaging bispecific antibodies (TCBs) represent a class of biopharmaceuticals that redirect cytotoxic T cells towards tumor cells, thereby turning immunologically "cold" tumors "hot." The carcinoembryonic antigen (CEA) is an attractive tumor-associated antigen (TAA) that is overexpressed in over 98% of CRC patients. In this study, we report the comparison of four different TCB formats employing the antibodies F4 (targeting human CEA) and 2C11 (targeting mouse CD3ε)...
April 18, 2024: Molecular Cancer Therapeutics
https://read.qxmd.com/read/38638003/mesenchymal-stromal-cells-increase-the-natural-killer-resistance-of-circulating-tumor-cells-via-intercellular-signaling-of-cgas-sting-ifn%C3%AE-hla
#20
JOURNAL ARTICLE
Ye Yi, Guihui Qin, Hongmei Yang, Hao Jia, Qibing Zeng, Dejin Zheng, Sen Ye, Zhiming Zhang, Tzu-Ming Liu, Kathy Qian Luo, Chu-Xia Deng, Ren-He Xu
Circulating tumor cells (CTCs) shed from primary tumors must overcome the cytotoxicity of immune cells, particularly natural killer (NK) cells, to cause metastasis. The tumor microenvironment (TME) protects tumor cells from the cytotoxicity of immune cells, which is partially executed by cancer-associated mesenchymal stromal cells (MSCs). However, the mechanisms by which MSCs influence the NK resistance of CTCs remain poorly understood. This study demonstrates that MSCs enhance the NK resistance of cancer cells in a gap junction-dependent manner, thereby promoting the survival and metastatic seeding of CTCs in immunocompromised mice...
April 18, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
keyword
keyword
99732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.